Cochrane Abstracts
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Prognostic Value of Test(s) for O6‐methylguanine–DNA Methyltransferase (MGMT) Promoter Methylation for Predicting Overall Survival in People With Glioblastoma Treated With Temozolomide." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6‐methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide.
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6‐methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide. Accessed December 13, 2024.
Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6‐methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide
Prognostic Value of Test(s) for O6‐methylguanine–DNA Methyltransferase (MGMT) Promoter Methylation for Predicting Overall Survival in People With Glioblastoma Treated With Temozolomide [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6‐methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
ID - 431926
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431926/all/Prognostic_value_of_test_s__for_O6‐methylguanine_DNA_methyltransferase__MGMT__promoter_methylation_for_predicting_overall_survival_in_people_with_glioblastoma_treated_with_temozolomide
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
